Comparative analysis of opicapone and entacapone in the management of motor fluctuations in patients with Parkinson’s disease, from clinical trials to healthcare resource usage
Daniel Kremens, Fahd Amjad, Sandeep Thakkar, Bita Naderi, Diogo Martins, José-Franciso Rocha, Ghazal Banisadr, Stanley Fisher
OPICAPONE as first strategy for the treatment of wearing-off in Korean patients with Parkinson’s disease
Jee-Young Lee, Joaquim J. Ferreira, Hyeo-il Ma, José-Francisco Rocha, Beomseok Jeon, on behalf of Korean OGT_001 study investigators
Evaluation of opicapone’s efficacy in Parkinson’s disease patients with motor fluctuations: phase III, randomized, double-blind, placebo- and active-controlled study (BIPARK I)
Joaquim Ferreira, Andrew Lees, Ana Santos, Roberto Pinto, Nelson Lopes, Teresa Nunes, Jose Rocha and Patrício Soares-da-Silva
This website and the information contained herein is intended for use by U.S. residents only. Amneal Pharmaceuticals’ rights to promote, offer for sale, and sell ONGENTYS is limited to the U.S.
Under license from 
Sign Up and Stay Connected
Sign up for the Expert Institute for Parkinson’s Disease newsletter
to receive product information, educational tools, resources, and more!